National Pharma Policy to harmonise drug standards with global norms, simplify licensing
The ministry wants the policy to simplify the licensing system to avoid duplication of efforts and ensure better coordination among different regulatory authorities
Lupin shares dip 4% on US FDA observations for Pithampur unit
The U.S. drug regulator has issued Form 483 with ten observations for Lupin’s Pithampur unit-2 manufacturing facility.
Now no customs duty on import of 'rare disease' medicines for personal use
A list out 51 medical problems including several metabolic disorders has been brought under the duty exempted category for import for personal use.
USFDA inspections to be less disruptive for Indian pharma sector: Report
Indian pharma companies have increasingly de-risked their operations by slowly and steadily increasing sales to non-US markets, says India Ratings and Research.
Lupin launches asthma drug DIFIZMA; stock gains
The pharma major has launched a novel fixed-dose triple drug combination ‘DIFIZMA’ to treat inadequately controlled asthma.
Sun Pharma gets U.S. FDA warning for Halol facility; share falls 2%
The pharma company received a warning letter from the U.S. FDA for violations of manufacturing standards at the Halol facility in Gujarat.
Lupin shares rise 4% on nod for Mirabegron tablets
Lupin has received U.S. FDA approval for Mirabegron Extended-Release Tablets used for the treatment of overactive bladder.
Traders’ body presses charges of 'drug peddling' against Amazon
CAIT demands action against senior management of the ecommerce giant after marijuana found in a fulfillment centre.
India can reprioritise its global commitments
In a post-coronavirus world, India can become a major provider of global public-goods and services like healthcare.